ISRCTN74427627已完成不适用
Multi-centre randomised placebo-controlled trial of corticosteroids in the prevention of coronary artery abnormalities in acute Kawasaki Disease (KD)
niversity of Leeds (UK)0 个研究点目标入组 1,306 人开始时间: 2005年11月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients aged one month to 16 years, inclusively, who present with either of the following (1. OR 2.):
- •1. A history of fever for at least four days, but not more than ten days, in addition to more than or equal to four of the five following features, identified by history and/or at presentation:
- •a. Oral mucosal changes ? any one of:
- •i. Redness, dryness, cracking, fissuring, peeling or bleeding of lips, or
- •ii. Diffuse redness of oral and pharyngeal mucosae, or
- •iii. Strawberry tongue (e.g. deep redness, prominent fungiform papillae)
- •b. Extremity changes ? redness of palms and soles, and/or induration (swelling) of hands and feet
- •c. Skin rash ? any rash that is non-vesicular and non-bullous
- •d. Conjunctivitis ? bilateral and non-purulent
- •e. Anterior cervical lymphadenopathy (any)
- •2. A history of fever for at least five days, but not more than ten days, in addition to three of the five features listed above AND any one of:
- •a. Serum C-Reactive Protein (CRP) more than or equal to 30 mg/l, or
- •b. Serum Erythrocyte Sedimentation Rate (ESR) more than or equal to 40 mm/hour, or
- •c. Plasma viscosity more than or equal to 1.7 mPa/s
- •Not all of these clinical features need be present at enrolment or at a single point in time.
- •'Fever' is considered to be pyrexia by history (e.g. tactile assessment by parent) OR by direct measurement. Whenever measured, fever is defined as a temperature of more than or equal to 38.0 °C (100.4 °F), determined by any method (e.g. oral, rectal, tympanic or axillary). A parental impression of pyrexia by tactile assessment alone can be taken as a day of fever, regardless of any measured temperature. The first day of fever is taken as the day on which the parent or guardian reports that the child first had a fever, either by history or recorded measurement.
排除标准
- •1. Fever for more than or equal to 11 days
- •2. Previous diagnosis of KD (e.g. recurrent disease or a second discrete symptomatic presentation of KD)
- •3. Clinical features suggesting disease other than KD, including any of:
- •a. Exudative conjunctivitis
- •b. Exudative pharyngitis
- •c. Exudative tonsillitis
- •d. Discrete intra-oral ulcerations or lesions
- •e. Bullous or vesicular rash
- •f. Hepatosplenomegaly and generalized adenopathy (e.g. inguinal and cervical)
- •4. Known or suspected acute diagnosis of:
- •a. Viral infection ? adenovirus, enteroviruses, Epstein-Barr Virus (EBV, infectious mononucleosis), CytoMegaloVirus (CMV), measles
- •b. Bacterial infection ? bacterial cervical adenitis, scarlet fever, staphylococcal scalded skin syndrome, toxic shock syndrome (S. aureus or group A streptococcus)
- •c. Rickettsial infection - leptospirosis, Rocky Mountain spotted fever
- •d. Drug hypersensitivity reaction
- •e. Stevens-Johnson Syndrome (SJS)
- •f. Juvenile Idiopathic Arthritis (JIA)
- •g. Leukaemia, lymphoma or other malignancy
- •h. Mercury hypersensitivity reaction (acrodynia)
- •5. Significant positive blood culture (single, non-contaminant organism)
- •6. Throat swab culture positive for group A streptococcus (Streptococcus pyogenes)
- •7. Positive Anti-Streptolysin-O titer (ASO titer)
- •8. Severe Congestive Heart Failure (CHF), with signs/symptoms present
- •9. Chronic renal failure
- •10. Liver failure
- •11. Severe systemic infection
- •12. Contraindication to systemic corticosteroid therapy:
- •a. History of allergic reaction (hypersensitivity) to intravenous methylprednisolone or one of its components
- •b. Severe allergy to an oral or intramuscular corticosteroid
- •c. Current treatment with any of: amphotericin, carbamazepine, cyclosporine, methotrexate
- •d. Active varicella infection
- •e. Exposure to case of varicella within the previous 21 days
- •13. Current oral, intravenous or intramuscular corticosteroid treatment
- •14. History of allergic reaction or severe systemic response to any human immune globulin preparation
- •15. Known Immunoglobulin A (IgA) deficiency or agammaglobulinaemia (antibody immune deficiency)
- •16. Lack of written informed parental consent
- •17. Enrolment in another study that might affect treatment delivery or efficacy or clinical follow-up
- •Administration of IVIG prior to enrolment does not necessarily exclude the child from enrolment in the trial. The presence of CA aneurysms on baseline echocardiogram is also not an exclusion criterion. However, any aneurysm must be documented by a study cardiologist.
研究者
相似试验
已完成
不适用
Multicentre randomised placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD)RespiratoryISRCTN23612807aval University (Canada)600
进行中（未招募）
1 期
Randomized, placebo-controlled multicenter trial of lithium plus treatment asusual (TAU) for acute suicidal ideation and behaviour in patients with suicidalmajor depressive episodeDiagnosis of a major depressive episodeinpatient at screening visitsuicidalideation/behaviour present defined by a clinical rating of = 8 on the SheehanSuicidality Tracking Scale (S-STS) at screening and a rating of =20 on the MontgomeryAsberg Depression Scale (MADRS) at both screening and baseline visitsbothgender, age =18 years.MedDRA version: 20.0Level: PTClassification code 10012397Term: Depression suicidalSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2013-000970-31-DETechnische Universität Dresden254
进行中（未招募）
1 期
Will Lactoferrin supplements prevent infections in premature babies?ate onset invasive infection in very preterm infantsEUCTR2012-004260-22-GBniversity of Oxford2,203
进行中（未招募）
不适用
Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS LithiumEUCTR2008-006722-34-ITISTITUTO SUPERIORE DI SANITA`
进行中（未招募）
1 期
AEUCTR2016-002072-26-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)450